VEGFR
All Product Categories
-
VEGFR Inhibitors
(337)
View all products
-
VEGFR Agonists
(5)
View all products
-
VEGFR Antagonists
(4)
View all products
-
VEGFR Activators
(7)
View all products
-
VEGFR Modulators
(6)
View all products
-
VEGFR Chemical
(1)
View all products
-
VEGFR Inducer
(1)
View all products
-
VEGFR Ligands
(3)
View all products
-
VEGFR Related Products (402)
Related Products (402)
-
Hypocrellin A (Standard)
0 ImagesCat. No.: HY-N2575RCAS No.: 77029-83-5Hypocrellin A (Standard) is the analytical standard of Hypocrellin A. This product is intended for research and analytical applications. Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and antiviral activities, especially against human immunodeficiency virus (HIV). In addition, Hypocrellin-A also possesses anti-Leishmania activity (IC50=0.27 μg/ml)[1][2][3][4][5][6][7][8][9].
-
Anti-VEGFR2/KDR/CD309 Antibody (AT001)
0 ImagesCat. No.: HY-P990543The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
-
Cabozantinib-d4 S-malate
0 ImagesCat. No.: HY-W706452Synonyms: XL184-d4 S-malate; BMS-907351-d4 S-malateCabozantinib-d4 (S-malate) (XL184-d4 (S-malate); BMS-907351-d4 (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
-
Vernodalin
0 ImagesCat. No.: HY-N19029CAS No.: 21871-10-3Vernodalin is an orally active, cytotoxic sesquiterpene lactone with a Kd value of 9.55 μM for p38 MAPK. Vernodalin downregulates the expression of phosphorylated ERK, JNK, AKT, PI3K, mTOR, p38MAPK, FAK, MMP-2, MMP-9, and uPA, while upregulates the expression of TIMP-1 and TIMP-2. Vernodalin increases ROS production, upregulates the expression of Bax and caspase 3, downregulates the expression of Bcl-2, and induces apoptosis (apoptosis), oxidative stress response and cell cycle arrest. Vernodalin inhibits the proliferation, adhesion and metastasis of cancer cells. Vernodalin enhances the activity of VEGF-B, AMPK and eNOS signaling pathways. Vernodalin alleviates myocardial injury and restores hemodynamic parameters. Vernodalin inhibits the growth of Trypanosoma brucei rhodesiense. Vernodalin can be used in research related to various cancers including gastric cancer, colorectal cancer and lung cancer, as well as African human trypanosomiasis and myocardial infarction.
-
XENP9493
0 ImagesCat. No.: HY-P992485XENP9493 is an IgG antibody against hVEGFA.
-
EGFR/VEGFR2-IN-8
0 ImagesCat. No.: HY-179140EGFR/VEGFR2-IN-8 (compound 10k) is a dual EGFR/VEGFR-2 inhibitor (EGFR IC50 = 57 nM, VEGFR-2 IC50 = 21 nM). EGFR/VEGFR2-IN-8 has anti proliferative activity against various tumor cells, such as MCF-7 (IC50 = 20 nM), Panc-1 (IC50 = 22 nM), A-549 (IC50 = 23 nM), HT-29 (IC50 = 23 nM) cells. EGFR/VEGFR2-IN-8 has antioxidant and apoptosis inducing activity. EGFR/VEGFR2-IN-8 can be used for research on various types of cancer.
-
Sotiburafusp alfa
0 ImagesCat. No.: HY-P990088CAS No.: 2637466-37-4Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa also functions as a PD-L1 inhibitor and a VEGF inhibitor.
-
VEGFR-2-IN-38
0 ImagesCat. No.: HY-157420CAS No.: 3020790-57-9VEGFR-2-IN-38 (compound 3) is a potential vascular endothelial growth factor receptor-2 inhibitor.
-
hCA/VEGFR-2-IN-4
0 ImagesCat. No.: HY-155763CAS No.: 2971782-83-7hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC50=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells.
-
Chloropyramine hydrochloride (Standard)
0 ImagesChloropyramine hydrochloride (Standard) is the analytical standard of Chloropyramine hydrochloride. This product is intended for research and analytical applications. Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of VEGFR-3 and FAK.
-
TG 100948
0 ImagesCat. No.: HY-W423707CAS No.: 1001341-27-0
-
Naphazoline-d4 hydrochloride
0 ImagesCat. No.: HY-111326SSynonyms: Naphthazoline-d4 hydrochlorideNaphazoline-d4 (hydrochloride) is the deuterium labeled Naphazoline hydrochloride.
-
hCA/VEGFR-2-IN-2
0 ImagesCat. No.: HY-155758CAS No.: 2971782-66-6hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC50=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells.
-
hPV19
0 ImagesCat. No.: HY-P992371
-
Bevasiranib
0 ImagesCat. No.: HY-153484CAS No.: 959961-96-7Bevasiranib is a siRNA that targets and silences VEGF-A. Bevasiranib activates the RNA-induced silencing complex to degrade VEGF-A mRNA, mediates TLR3-related inhibition of choroidal neovascularization, and triggers RNA interference-mediated gene silencing through endogenous eukaryotic RNAi mechanisms. After intravitreal injection, Bevasiranib distributes to various ocular tissues and resists degradation by intraocular nucleases, reducing choroidal neovascularization area and alleviating vascular leakage. Bevasiranib can be used in research related to macular degeneration.
-
Anti-VEGFR1/FLT1 Antibody
0 ImagesCat. No.: HY-P990541Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
-
Toceranib-d8
0 ImagesToceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
-
Vandetanib-d4
0 ImagesCat. No.: HY-10260S1CAS No.: 1215100-18-7Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM).
-
CDK2/FLT4/PDGFRA-IN-1
0 ImagesCat. No.: HY-173124CDK2/FLT4/PDGFRA-IN-1 (Compound 4a) is a potent inhibitor of CDK2/cyclin A, FLT4 (VEGFR3) and PDGFRA, with IC50s of 1.672, 0.554, and 0.629 μM, respectively. CDK2/FLT4/PDGFRA-IN-1 exhibits potent antiproliferative effects against cancer cells (lung EBC-1, pancreatic ductal adenocarcinoma AsPC-1, colorectal HT-29 cells). CDK2/FLT4/PDGFRA-IN-1 can also induce apoptosis in cancer cells.
